← Leaderboards
Michael P Pollastri
Boston University (Charles River Campus)
$8,526,266
Attributed
$14,854,784
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2009–22$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$14,854,784 · 9
By mechanism
R01$12,924,166 · 5
R21$824,884 · 2
R56$672,488 · 1
R33$433,246 · 1
Top collaborators
- Kojo Mensa-Wilmot9 shared
- Robert Kirwan Campbell8 shared
- Miguel A Navarro4 shared
- Julia R Koehler3 shared
- Stephen L Hajduk1 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsToxic EffectPharmaceutical ChemistryLeadDrug DiscoveryParasitesPropertyCellsSeriesDoseAfrican TrypanosomiasisDesignTrypanosoma Brucei BruceiDrug KineticsInhibitor/AntagonistIn VitroScreeningPre-ClinicalBlood CirculationIndustrySolubilityFundingOralAffect
Grant awards (32)
Inhibiting sequential biosynthetic steps of a fungal-specific organelle$450,754
R01 · FY2022 · AI
Optimization and Modes of Action of NEU-4438, a New Anti-trypanosome Lead Drug$688,344
R01 · FY2021 · AI
Inhibiting sequential biosynthetic steps of a fungal-specific organelle$473,764
R01 · FY2021 · AI
Repurposing human kinase inhibitor chemotypes for Neglected Tropical Diseases$464,233
R01 · FY2021 · AI · contact PI
Lead optimization of hits identified from virtual and experimental screens of multiple industrial libraries DNDi$433,246
R33 · FY2021 · AI · contact PI
Curaxin-137, A New Lead for Anti-Trypanosome Drug Discovery - Resubmission - 1$638,391
R01 · FY2020 · AI
Inhibiting sequential biosynthetic steps of a fungal-specific organelle$510,459
R01 · FY2020 · AI
Lead optimization of hits identified from virtual and experimental screens of multiple industrial libraries DNDi$200,954
R21 · FY2020 · AI · contact PI
Hit-to-lead optimization for sleeping sickness drug discovery$690,774
R01 · FY2019 · AI · contact PI
Curaxin-137, A New Lead for Anti-Trypanosome Drug Discovery - Resubmission - 1$647,208
R01 · FY2019 · AI
Hit-to-lead discovery for sleeping sickness via industry-academic partnership$475,385
R01 · FY2019 · AI · contact PI
Lead optimization of hits identified from virtual and experimental screens of multiple industrial libraries DNDi$197,029
R21 · FY2019 · AI · contact PI
Curaxin-137, A New Lead for Anti-Trypanosome Drug Discovery - Resubmission - 1$686,979
R01 · FY2018 · AI
Hit-to-lead optimization for sleeping sickness drug discovery$662,424
R01 · FY2018 · AI · contact PI
Hit-to-lead discovery for sleeping sickness via industry-academic partnership$475,385
R01 · FY2018 · AI · contact PI
Lead optimization of agents targeting multiple kinetoplastid parasites$266,948
R21 · FY2018 · AI · contact PI
Curaxin-137, A New Lead for Anti-Trypanosome Drug Discovery - Resubmission - 1$697,985
R01 · FY2017 · AI
Hit-to-lead optimization for sleeping sickness drug discovery$616,674
R01 · FY2017 · AI · contact PI
Hit-to-lead discovery for sleeping sickness via industry-academic partnership$521,683
R01 · FY2017 · AI · contact PI
Lead optimization of agents targeting multiple kinetoplastid parasites$159,953
R21 · FY2017 · AI · contact PI
Hit-to-lead optimization for sleeping sickness drug discovery$640,299
R01 · FY2016 · AI · contact PI
Hit-to-lead discovery for sleeping sickness via industry-academic partnership$475,385
R01 · FY2016 · AI · contact PI
Hit-to-lead discovery for sleeping sickness via industry-academic partnership$554,299
R01 · FY2015 · AI · contact PI
Lead Optimization of Lapatinib Analogs for Human African Trypanosomiasis$672,488
R56 · FY2014 · AI
Validation and development of trypanosomal phosphodiesterase inhibitors for treat$404,894
R01 · FY2013 · AI · contact PI
Validation and development of trypanosomal phosphodiesterase inhibitors for treat$457,655
R01 · FY2012 · AI · contact PI
Validation and development of trypanosomal phosphodiesterase inhibitors for treat$537,683
R01 · FY2011 · AI · contact PI
Validation and development of trypanosomal phosphodiesterase inhibitors for treat$536,539
R01 · FY2010 · AI · contact PI
Validation and development of trypanosomal phosphodiesterase inhibitors for treat$354,990
R01 · FY2009 · AI · contact PI
Validation and development of trypanosomal phosphodiesterase inhibitors for treat$196,147
R01 · FY2009 · AI · contact PI
Validation and development of trypanosomal phosphodiesterase inhibitors for treat$39,583
R01 · FY2009 · AI · contact PI
Validation and development of trypanosomal phosphodiesterase inhibitors for treat$26,250
R01 · FY2009 · AI · contact PI